Radioimmunotherapy in relapsed follicular lymphoma previously treated by autologous bone marrow transplant: a report of eight new cases and literature review
Authors:
- Frederic PeyradeFPFrederic Peyrade
- Caroline TribyCTCaroline Triby
- Bohane SlamaBSBohane Slama
- Xavier FontanaXFXavier Fontana
- Remy GressinRGRemy Gressin
- Jean-Marc BrogliaJBJean-Marc Broglia
- Gérard LepeuGLGérard Lepeu
- Patricia CarrierPCPatricia Carrier
- Isabelle PeyrottesIPIsabelle Peyrottes
- Jacques DarcourtJDJacques Darcourt
- Pierre-Yves BondiauPBPierre-Yves Bondiau
- Antoine ThyssATAntoine Thyss
- 1 January 2008
- journal article
- case report
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 49 (9) , 1762-1768
Abstract
Multicenter, retrospective study of standard-dose RIT in eight heavily pre-treated patients with CD20-positive follicular lymphoma who had relapsed after previous autologous bone marrow transplantation (ABMT). Patients underwent nine courses of (90)Y-ibritumomab tiuxetan (0.3 or 0.4 mCi/kg body weight). Responses included five CR, two PR, one SD and one PD. Median DFS was 12 months with median follow-up of 17 months and 1-year OS was 83% (7/8 patients). Grade 4 thrombocytopenia occurred in 7/9 treatments, with no episodes of bleeding, and only two patients received a platelet transfusion. One patient, who had 20% bone marrow involvement at the time of relapse diagnosis, presented with Grade 4 thrombocytopenia and Grade 4 neutropenia and died of septic shock 6 months after RIT. One other case of Grade 4 neutropenia, without a serious infectious syndrome, was observed. Standard-dose RIT seems feasible and potentially effective after ABMT in correctly selected patients with follicular lymphoma.Keywords
This publication has 26 references indexed in Scilit:
- Long-Term Survival after Autologous Bone Marrow Transplantation for Follicular Lymphoma in First RemissionTransplantation and Cellular Therapy, 2007
- Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d'Etude des Lymphomes de l'Adulte (GELA)Blood, 2006
- Long-term complete responses after 131I-tositumomab therapy for relapsed or refractory indolent non-Hodgkin's lymphomaBritish Journal of Cancer, 2006
- Improvement of Overall and Failure-Free Survival in Stage IV Follicular Lymphoma: 25 Years of Treatment Experience at The University of Texas M.D. Anderson Cancer CenterJournal of Clinical Oncology, 2006
- Tositumomab and Iodine-131 Tositumomab Produces Durable Complete Remissions in a Subset of Heavily Pretreated Patients With Low-Grade and Transformed Non-Hodgkin’s LymphomasJournal of Clinical Oncology, 2005
- High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GOELAMSBlood, 2005
- Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 studyBlood, 2004
- Tositumomab and Iodine I 131 Tositumomab for Recurrent Indolent and Transformed B-Cell Non-Hodgkin’s LymphomaJournal of Clinical Oncology, 2004
- High-Dose Therapy Improves Progression-Free Survival and Survival in Relapsed Follicular Non-Hodgkin’s Lymphoma: Results From the Randomized European CUP TrialJournal of Clinical Oncology, 2003
- High-dose therapy with autologous stem-cell transplantation (ASCT) after first progression prolonged survival of follicular lymphoma patients included in the prospective GELF 86 protocolAnnals of Oncology, 2000